Datar Cancer Genetics Unveils Exacta AI: A Revolutionary AI-Driven Cancer Treatment Platform

Metropolis Healthcare Partners with Roche to Launch Self-Sampling HPV DNA Test for Cervical Cancer Screening in India

Union Budget 2025: Full Exemption from Basic Customs Duty (BCD) for 36 Lifesaving Drugs

Dr. Jitendra Singh Inaugurates Centre for Advanced Genomics & Precision Medicine at AIIMS Jammu

Union Budget 2025-26: Key Healthcare Measures for Cancer Care and Access to Life-Saving Drugs

FDA Approves Roche’s PATHWAY HER2 Test for Identifying HER2-Ultralow Breast Cancer Patients Eligible for ENHERTU

Bristol Myers Squibb’s Breyanzi® Receives CHMP Recommendation for Relapsed or Refractory Follicular Lymphoma in the EU

NHS to Offer Groundbreaking Gene Therapy for Sickle Cell Disease

Quibim Secures $50M Series A to Advance AI-Powered Imaging for Precision Medicine

Apollo Hospitals Unveils Advanced Oncology Facility in Chennai

Beckman Coulter’s Alzheimer’s Blood Test Receives FDA Breakthrough Device Designation

ANGLE Announces Breakthrough Dual CTC-DNA and ctDNA Analysis with Illumina’s NGS Solution

Diatech Pharmacogenetics and Merck Expand Collaboration to Enhance RAS Biomarker Testing in MEA Region

DCG Unveils AI-Powered Video-Reporting for Personalized Chemotherapy Selection

FDA Approves Monthly Maintenance Dosing for LEQEMBI® in Alzheimer’s Treatment

Home
/
update
/
details

Sanofi Invests $40M in Vigil Neuroscience, Securing Exclusive License Option to TREM2 Program

NextEdge Admin

29 Jun 2024

2 min 25 sec

Sanofi, based in Paris, has invested $40 million in Vigil Neuroscience through the purchase of 537,634 Series A non-voting preferred shares at $7.44 per share. Each of these shares can be converted into 10 common shares of Vigil's stock. The investment will primarily fund the clinical development of multiple agents within Vigil's pipeline, focusing notably on an Alzheimer's drug targeted at a genetically defined population.

Vigil's flagship candidate, VG-3927, operates within its small molecule TREM2 agonist program, aiming to address dysfunctional microglia—a critical type of immune cell in the central nervous system. The drug is currently undergoing Phase I clinical trials among healthy adults. Research indicates that normally functioning microglia play a role in reducing beta-amyloid plaque levels in the brain, while a functional TREM2 is essential in preventing tau protein aggregates linked to Alzheimer's disease.

Sanofi's investment not only supports Vigil's immediate financial needs but also grants Sanofi the exclusive right to negotiate the licensing of agents from Vigil's TREM2 agonist program. Erik Wallstroem, Sanofi's global head of neurology development, emphasized the significance of microglial signaling and neuroinflammation in neurodegenerative diseases, underlining Sanofi's deepened commitment to immunoscience and neuroimmunology through this partnership.

Headquartered in Watertown, Massachusetts, Vigil anticipates that the infusion of funds will extend its financial runway through 2026. This strategic collaboration marks a significant step forward in advancing therapies targeting Alzheimer's and related conditions by leveraging insights into the role of microglia and TREM2 signaling pathways in neurodegenerative processes.